Deutsche Bank analyst Emmanuel Papadakis upgraded Sandoz (SDZNY) to Buy from Hold with a price target of CHF 42, up from CHF 36. The company’s mid-single-digit revenue guidance will likely prove conservative and its biosimilar outlook “remains appealing,” the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDZNY:
- Sandoz price target lowered to CHF 38 from CHF 41 at Morgan Stanley
- Sandoz Group Reports Strong Growth and Strategic Advancements
- Sandoz Group Ltd: Strong Financial Performance and Resilient Outlook Justify Buy Rating
- Sandoz launches Pyzchiva in the U.S.
- Sandoz price target raised to CHF 41 from CHF 35 at Morgan Stanley